Monoclonal antibodies to risk gene IL2Ra (drug Daclizumab) and to CD49D, ligand of risk gene VLA4 (drug Natalizumab), are effective therapies for MS [2]. This evidence concerns the gene ITGA4 and myeloid sarcoma.